Loss-of-function mutations in BAP1 result in loss of deubiquitination activities, disrupting various cellular processes including cell cycle, therefore driving tumourigenesis1 in many cancers such as renal cell carcinoma, mesothelioma, uveal melanoma, small cell and non-small-cell lung cancers and cholangiocarcinoma11–14. This evidence concerns the gene BAP1 and cancer.